EP071/#406 Assessing geographic variation in rates of recurrent or metastatic cervical cancer (based on commencement of systemic therapy) among medicaid enrollees

Abstract

PIK3CA (40.8%), TP53 (34.7%), PIK3R1 (12.2%), FAT1 (12.2%), FBXW7 (10.2%), and PTEN (10.2%). For CNV, the most frequent mutation was CCNE1 amplification (4 out of 10 patients, 40% of tested). In terms of treatment, 18 patients received immunotherapy with PD1 or PD-L1 as targets, and 5 patients are still ongoing. Median PFS for immunotherapy overall was 3.5 months (range: 0.5-22.3). Conclusions For patients with cervical cancer, tumor NGS and IHC profile may help identify potential candidate for targeted therapy and immunotherapy.